Dupixent Lawsuit in Kansas - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Kansas's proximity to the Kansas City metropolitan area — straddling the Kansas-Missouri border — gives Kansas Dupixent patients access to the University of Kansas Cancer Center, the only NCI-designated cancer center in the region. An estimated 22,000 Kansans have been prescribed Dupixent since 2017, with prescribing concentrated in the Kansas City metro and Wichita areas. Kansas's product liability framework includes a 10-year statute of repose that could affect claims from early Dupixent adopters. The District of Kansas in Kansas City and Wichita handles moderate pharmaceutical litigation volume, and Kansas's generally conservative jury pools may be less favorable to plaintiffs than coastal venues, though the evidence of a drug causing cancer in eczema patients tends to transcend political orientation in jury deliberations.

Written By

People's Justice Legal Research Team

Statute of Limitations

Kansas: 2 years for product liability (Kan. Stat. Ann. § 60-513(a)(4)). Discovery rule applies — the statute begins when the plaintiff discovers or should have discovered the injury and its causal relationship to the product.

2 years from discovery of injury

Filing Venue

Where to File in Kansas

Kansas has a single federal judicial district — the District of Kansas, headquartered in Kansas City (Kansas side) and Wichita. Kansas follows a modified comparative fault system (50 percent bar). Kansas applies the Product Liability Act (Kan. Stat. Ann. § 60-3301 et seq.) and has a 10-year statute of repose for product liability claims.

Kansas Data

Exposure in Kansas

Source: IQVIA prescription data estimates

Source: University of Kansas Cancer Center / NCI

Source: Kan. Stat. Ann. § 60-3303(a)

FAQ

Frequently Asked Questions

See details below.

Back to Dupixent Lawsuit Lawsuit Overview